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Abstract 
Mucus is a highly hydrated viscoelastic gel present on various moist surfaces in our body 
including the eyes, nasal cavity, mouth, gastrointestinal, respiratory and reproductive tracts. It 
serves as a very efficient barrier that prevents harmful particles, viruses and bacteria from 
entering the human body. However, the protective function of the mucus also hampers the 
diffusion of drugs and nanomedicines, which dramatically reduces their efficiency. 
Functionalisation of nanoparticles with low molecular weight poly(ethylene glycol) 
(PEGylation) is one of the strategies to enhance their penetration through mucus. Recently a 
number of other polymers were explored as alternatives to PEGylation. These alternatives 
include poly(2-alkyl-2-oxazolines), polysarcosine, poly(vinyl alcohol), other hydroxyl-
containing non-ionic water-soluble polymers, zwitterionic polymers (polybetains) and 
mucolytic enzymes. This review discusses the studies reporting the use of these polymers or 
potential application to facilitate mucus permeation of nanoparticles.  
 
Keywords: mucus, mucoadhesion, mucus-penetrating nanoparticles; stealth polymers; 
poly(2-alkyl-2-oxazolines); zwitterionic polymers 
1. Introduction 
Drug delivery via mucosal routes offers numerous advantages, including improved drug 
bioavailability, ease of administration and possibility for quick therapy termination   [1-11]. 
Transmucosal delivery is less invasive compared to injections that often helps to improve 
patient compliance. Mucosal routes of drug administration currently used include ocular, 
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nasal, oromucosal, pulmonary, gastrointestinal, vaginal, rectal and intravesical.  Some of 
these routes offer a possibility of targeting particular organs. For example, topical 
administration to the eye allows targeting some intraocular tissues [12, 13]; nasal 
administration provides a direct access to central nervous system [14, 15]; and intravesical 
administration gives a possibility to reach the urinary bladder [16, 17]. 
Mucosal membranes covering the moist surfaces in the human body have numerous roles and 
functions, including protection of cellular epithelia from chemical and mechanical damage. 
They also provide lubrication and regulate moisture content in the underlying tissues, and 
prevent penetration of various environmental particles, viruses and bacteria [1, 2, 7]. In the 
stomach the mucus gel plays an important role in protecting epithelium from acid self-
digestion [18] and also facilitates the transport of undigested boluses of food by its 
lubrication. In the intestinal tract the mucus gel serves as a medium for colonisation by 
“healthy” bacteria such as probiotics while acting as a barrier for pathogenic bacteria [19]. In 
the female reproductive tract the cervicovaginal mucin secretions limit the mobility of sperm 
outside the ovulatory phase but before ovulation the mucus becomes thinner and more 
permeable [20].    
Mucus gel layer covering the surfaces of mucosal membranes is a dynamic system that is 
continuously reformed through secretion of mucins by the goblet cells. The life-time of 
mucus gel layer is typically very short and varies in different parts of human body. For 
example, in the eye it is around 5.0-7.7 min; in the respiratory tract it is 10-20 min and in the 
gastrointestinal tract it is 4-6 hours [21]. The protective function of the mucus also hampers 
the diffusion of drugs and nanomedicines, which dramatically reduces their efficiency [22, 
23].  
The ability of different materials, such as some polymers, to adhere and retain on the surface 
of mucosal membranes has been often utilised in transmucosal delivery to improve drug 
bioavailability [1, 2, 24]. Examples of successful commercial applications of mucoadhesive 
formulations include Buccastem buccal tablets (Reckitt Benckiser) for the treatment of 
nausea and vomiting, AzaSite® ophthalmic solution (InSite Vision) for the treatment of 
bacterial conjunctivitis; Sinol-M (Sinol USA Inc) spray for the relief of nasal allergies; and 
NyQuil® cough relief syrup (Procter & Gamble). However, despite the numerous advances 
in the area of transmucosal drug delivery, there a number of factors that limit further 
developments and efficiency of novel systems. The short life-time and fast clearance of 
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mucus does not allow many dosage forms to retain on mucosal surfaces to provide sustained 
drug delivery and the sticky and viscoelastic nature of mucus prevents drug molecules and 
especially nano-carriers from reaching the epithelial cells. 
The development of systems facilitating the efficient diffusion of active ingredients through 
the mucus is important in drug delivery to the airways [25].  The efficient diffusion of drug 
and gene delivery systems through the mucus in the airways may lead to the breakthrough in 
the treatment of cystic fibrosis, one of the life-threatening inherited conditions, that causes 
the body to produce excessive quantities of thick mucus that blocks the lungs, affects the 
digestive tract and some other organs or functions [26, 27]. The development of 
nanomedicines capable of “slipping” through the mucus will also be of immense benefit for 
the treatment of patients suffering from various forms of nasal disorders such as excessive 
mucus secretion, congestion and obstruction caused by allergic rhinitis. Another relevant 
therapeutic area is the drug delivery to the vagina, where there is an urgent need in the 
development of novel and efficient microbicides that are promising for preventing 
transmission of HIV and other sexually transmitted pathogens [20]. Vaginal microbicides 
with excellent diffusive characteristics are expected to demonstrate significantly higher 
efficiency [28]. Efficient mucus penetration is also beneficial for drug delivery in the 
gastrointestinal tract, for example, for potential eradication of helicobacter pylori infections 
[29].  
A major breakthrough in the enhancement of diffusivity of nanomaterials through mucus has 
been reported by the group of Hanes [30-34]. In a series of studies they demonstrated that 
220 nm carboxylated polystyrene nanoparticles, that exhibit poor ability to diffuse in mucus, 
can be functionalised with low molecular weight poly(ethyleneglycol) (PEG), which 
efficiently enhances their penetration ability. The PEGylated nanoparticles have hydrophilic 
and near neutrally-charged surfaces that reduce mucoadhesion by preventing hydrophobic or 
electrostatic interactions, which mimics the ability of pathogenic microorganisms to slip 
through mucus. Additionally, depending on the molecular weight (Mw) of PEG, the 
nanoparticles can be made mucus-penetrating (when Mw is 2,000 Da) or mucoadhesive 
(when Mw is 10,000 Da) [30]. More recently, Hanes et al [35] also demonstrated that 
densely-grafted PEG of 10-40 kDa can also enhance nanoparticle diffusion through human 
cervicovaginal mucus ex vivo and through mouse colorectal and vaginal epithelium in vivo. 
Many other studies demonstrated the use of PEGylation to enhance mucus and other tissue 
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penetration to facilitate drug delivery to the lung [36], the gastrointestinal tract [37, 38] and 
the eye [39-41].  
Figure 1 illustrates the concept of enhanced penetration of nanoparticles coated with 
inert polymers such as low molecular weight PEG or potentially any other non-mucoadhesive 
macromolecules. The mucoadhesive particles will typically stick to the components of  
mucus gel and will show lower potential for penetration, whereas non-mucoadhesive particles 
coated with inert polymers will be able to efficiently move through this barrier. 
 
Figure 1. Schematic illustration of nanoparticles penetration through mucus lining. This 
image was produced by Ella Maru Studio, http://www.scientific-illustrations.com/portfolio 
 
   
 
 
 
2. New polymers for developing mucus-penetrating nanoparticles 
 
2.1. Poly(2-alkyl-2-oxazolines) 
Poly(2-alkyl-2-oxazolines) (POZ) is a class of polymers with polypeptide-isomeric structures 
that have recently attracted a lot of attention as materials for biomedical applications [42-44].  
The synthesis of these materials was first reported in the 1960s using cationic ring-opening 
polymerisation of different 2-oxazoline derivatives (Figure 2).  
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Figure 2. Synthesis of poly(2-alkyl-2-oxazolines) (a); structures of water-soluble poly(2-
alkyl-2-oxazolines) 
In recent years, poly(2-alkyl-2-oxazolines) were recognised as non-toxic and biocompatible 
materials with excellent “stealth” behaviour similar to PEG [42]. Methyl-, ethyl and n-propyl 
derivatives of POZ are soluble in water; PEOZ and PNPOZ exhibit lower critical solution 
temperature (LCST) in aqueous solutions at around 61-64 C and 25-25 C, respectively.  
Poly(2-alkyl-2-oxazolines) are not currently FDA approved; however, their extensive 
research for pharmaceutical applications may facilitate their regulatory clearance within the 
next few years [45]. In fact, some poly(2-ethyl-2-oxazoline)-containing formulations are 
currently undergoing clinical trials [46].  
Mansfield et al [47, 48] reported the development of thiolated silica nanoparticles, their 
functionalisation with poly(2-methyl-2-oxazoline) (PMOZ), poly(2-ethyl-2-oxazoline) 
(PEOZ), and poly(2-n-propyl-2-oxazoline) (PNPOZ), in vitro diffusion studies in porcine 
gastric mucin dispersions, and ex vivo diffusion studies into porcine gastric mucus. Thiolated 
silica nanoparticles were synthesised by self-condensation of 3-
mercaptopropyltrimethoxysilane (MPTS) in dimethylsulfoxide in the presence of atmospheric 
oxygen to mediate their partial cross-linking via disulfide bringing [49]. The presence of thiol 
groups on the surface of these nanoparticles ensured their excellent mucoadhesive properties 
[49, 50] and also provided opportunity for their surface PEGylation and POZylation by 
reactions with maleimide-terminated PEG and alkyne-terminated POZ. Mansfield et al [47, 
48] studied the diffusion of these nanoparticles first in porcine gastric mucin dispersions 
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using nanoparticle tracking analysis, and then evaluated their penetration into freshly excised 
porcine stomach mucosa. Figure 3 shows the diffusion coefficients of the nanoparticles in 
porcine gastric mucin and average distances travelled by the nanoparticles through mucus 
gel.   
 
 
Figure 3. (a) Diffusion coefficients for thiolated, and poly(2-oxazoline)-functionalised silica 
nanoparticles through a 1% gastric mucin dispersion at 25 and 37 °C. Error bars represent the 
mean ± standard deviation of 3 repeats; (b) Ex vivo penetration of thiolated and poly(2-
oxazoline)-functionalised silica nanoparticles into porcine gastric mucosa over 1 hour. Values 
represent the mean penetration across 10 separate tissue sections ± standard deviation. 
7 
 
Reprinted from Biomater. Sci., 2016, 4, 1318–1327 [47] with permission by the Royal 
Society of Chemistry.  
 
Both techniques demonstrated poor diffusivity of thiolated nanoparticles, which is consistent 
with their excellent mucoadhesive properties. The nanoparticles functionalised with PMOZ 
exhibited excellent mobility in the mucus, which was even superior to PEGylated sample of 
similar size. The nanoparticles with PEOZ surface were also significantly more diffusive 
compared to thiolated sample, but the ability of PEOZ to facilitate diffusion in the mucus was 
lower than what was recorded for PMOZ. The nanoparticles with PNPOZ surface did not 
show a significant difference in diffusion coefficient to the thiolated silica particles; however 
there was a significant difference in their penetration through gastric mucosa at longer time 
periods. Mansfield et al [47] related these observations to the changes in the hydrophobic–
hydrophilic balance of poly(2-oxazolines): more hydrophilic polymers exhibited better ability 
to enhance mucus penetration.  
 
2.2. Polypeptides and polypeptoids 
Synthetic polypeptides and polypeptoids (Figure 4) are biodegradable biopolymers with 
structures mimicking natural proteins [51]. Polypeptoids is a class of pseudo-peptidic 
polymers that have an aliphatic polyamide backbone with some substitution on the nitrogen 
atoms [52].  
 
Figure 4. Structures of polypeptides, polypeptoids and polysarcosine (poly(N-methylglycine) 
 
Polysarcosine (poly(N-methylglycine)) is a non-ionic water-soluble and biocompatible 
polypeptoid that has been explored for functionalisation of surfaces and nanoparticles for 
application in biomedicine [53, 54]. Lau et al [55] demonstrated that surface-grafted 
polysarcosine (PS) brushes exhibit excellent resistance to nonspecific protein adsorption and 
cell attachment. Although there are currently no reports on the use of PS or any other 
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polypeptoids for particle functionalisation to facilitate their diffusion through mucus, these 
materials are believed to be promising for application in transmucosal drug delivery. 
 
2.3. Poly(vinyl alcohol) 
Poly(vinyl alcohol) (PVA) is a non-ionic water-soluble polymer that has widely been used as 
a component of biomaterials and various drug delivery systems [56-61]. PVA often exhibits 
surface-active properties, making this polymer suitable as an emulsifier for stabilising various 
colloidal systems [62, 63].   
PVA cannot be synthesised by direct polymerisation of vinyl alcohol because of unstable 
nature of this monomer [64]; instead this polymer is typically synthesised by polymerisation 
of poly(vinyl acetate), with its subsequent hydrolysis (saponification) to form poly(vinyl 
alcohol) (Figure 5). By this reason, PVA often contains residual vinyl acetate groups that 
greatly influence its physicochemical properties.  
 
Figure 5. Synthesis and structure of poly(vinyl alcohol) 
Another important feature of PVA is its semi-crystalline nature, which affects its solubility in 
water. PVA with larger molecular weights and higher degrees of crystallinity can be 
dissolved in water only upon heating to above 80-85 C to disrupt strong intermolecular 
hydrogen bonding and crystallinity in solid polymer; subsequent cooling to a room 
temperature results in formation of stable aqueous solutions. Freezing aqueous solutions 
containing PVA and their subsequent thawing often results in formation of physically cross-
linked cryogels, which could be used in drug delivery [65], biomaterials [66] and wound care 
[67]. PVA is a biocompatible and bioinert material, which makes this polymer to be highly 
suitable for many biomedical applications.  
Yang et al [68] evaluated the diffusion of 200 nm carboxylated polystyrene nanoparticles 
coated with 2 kDa, 6 kDa, 25 kDa and 78 kDa PVA through human cervicovaginal mucus. 
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They also compared the behaviour of these particles with PEGylated polystyrene and 
PEGylated poly(lactide-co-glycolide) (PLGA) particles. They established that coating of 
carboxylated polystyrene nanoparticles with PVA of different molecular weight did not 
provide any improvement in their mucus diffusivity: there was no statistically significant 
difference between the mobility of carboxylated polystyrene and the nanoparticles coated 
with various grades of PVA in the mucus. Both carboxylated polystyrene and PVA-coated 
nanoparticles remained relatively immobile in the mucus, contrary to excellent diffusion 
properties of PEGylated nanoparticles of similar size. The authors have also evaluated the 
effect of PVA on mucus penetration properties of PEGylated PLGA nanoparticles. The 
deposition of PVA on the surface of PEGylated PLGA dramatically reduced their mucus 
penetration ability. The authors concluded that PVA exhibits mucoadhesive properties 
regardless of its molecular weight; these properties are likely to be due to the ability of this 
polymer to form hydrogen bonds and hydrophobic contacts with the components of the 
mucus gel. They also demonstrated that the degree of PVA deacetylation has a strong effect 
on the diffusivity of PVA-coated particles in the mucus. Polystyrene nanoparticles coated 
with 25 kDa 98% hydrolysed PVA were found to show greater mucus diffusivity compared 
to 25 kDa 88 % hydrolysed PVA.    
More recently, Popov et al [69] reported a more detailed ex vivo study exploring the effect of 
10 different grades of PVA on the diffusivity of carboxylated polystyrene and polylactide 
(PLA) nanoparticles in ovulatory human cervicovaginal mucus. They prepared polystyrene 
particles coated with PVA by incubation of carboxylated polystyrene particles in PVA 
solutions (0.4-0.5 % w/w) in deionised water for 24 hours at room temperature. The PVA-
coated PLA nanoparticles were prepared by emulsification-evaporation procedure involving 
dissolution of PLA in dichloromethane, its emulsification in aqueous solution of PVA, 
sonication and subsequent rotary evaporation. It was established that some nanoparticles 
coated with PVA exhibited excellent ability to move through cervicovaginal mucus similarly 
to control PEGylated polystyrene particles; whereas other samples were mostly immobilised 
in the mucus. Figure 6 shows the map of the ability PVA coated nanoparticles to exhibit 
mucus-penetration or mucoadhesion as a function of PVA molecular weight and degree of 
hydrolysis. The PVAs with the degree of hydrolysis > 90 % were found to be mucoadhesive 
and the PVAs containing greater number of residual vinyl acetate groups exhibited mucus 
penetration character. The authors related this observation to relatively hydrophobic 
properties of vinyl acetate that provide better shielding effect, which prevents this polymer 
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from hydrogen bonding with mucins.  It should be noted that the results of Popov et al [69] 
contradict some of the findings reported by Yang et al [68]. Popov et al [69] explained this 
discrepancy by the difference in the particle purification protocols used resulting in a 
different density of PVA coating.  
 
 
 
Figure 6. Mucus-penetrating (solid symbols) and mucoadhesive (open symbols) behaviour of 
nanoparticles mapped with regard to the PVA’s molecular weight (MW) and hydrolysis 
degree (degree of deacetylation). Circles represent carboxylated polystyrene nanoparticles 
incubated with various PVAs; Triangles represent PLA nanoparticles prepared by 
emulsification with various PVAs. Essentially identical behaviour was observed in both 
systems: PVAs with hydrolysis degrees < 95% and at least as low as 75%, regardless of their 
MW, produced particles as mobile (or nearly as mobile) in cervicovaginal mucus as the 
positive control (PEGylated polystyrene nanoparticles). Reprinted from Nanomedicine: 
Nanotechnology, Biology and Medicine, Vol 12, A. Popov, E. Enlow, J. Bourassa, H. Chen, 
Mucus-penetrating nanoparticles made with “mucoadhesive” poly(vinyl alcohol), 1863-1871 
[69], Copyright (2016), with permission from Elsevier.   
More studies will be necessary to evaluate the mucus-penetrating potential of PVA. These 
studies should include different mucosal routes and should also use better defined PVA 
samples. Some methods for the synthesis of well-defined PVA were developed [70, 71], 
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which could be useful for producing PVA samples with controlled molecular weights and 
polydispersities. 
 
2.4. Other polymers with hydroxyl side groups 
Poly-(N-(2-hydroxypropyl)methacrylamide) (PHPMA) is another water-soluble polymer that 
was first synthesized by Kopeček et al in 1973 and was extensively studied for various 
biomedical applications (Figure 7) [72]. PHPMA can be easily synthesised using 
conventional free radical polymerisation, atom transfer radical polymerisation (ATRP), and 
reversible addition-fragmentation chain transfer (RAFT) polymerisation of N-(2-
hydroxypropyl)methacrylamide) [73]. The reactive hydroxyl group present in PHPMA can be 
subsequently exploited for further polymer functionalisation by conjugation with drugs, 
fluorescent labels, and other useful functional molecules. PHPMA has a number of 
advantages over PEG, as it does not show dose-dependent immunoresponses, rapid clearance 
after repeated injections, and potential oxidation. PHPMA also exhibits “stealth” properties 
similar to PEG [74, 75]. PHPMA has found applications for development of polymer-drug 
and polymer-protein conjugates, self-assembled nanoparticles, hydrogels and other systems 
[72, 73].  
Shan et al [76] reported the development of self-assembled nanoparticles with excellent 
mucus permeating properties for oral delivery of insulin. The nanoparticles were prepared by 
mixing the aqueous solutions of insulin with penetratin, a polycationic peptide with cell-
penetrating properties. The positively-charged nanocomplexes formed were then added to the 
solutions of negatively-charged HPMA copolymers with N-methacryloylglycilglycine 
(MAGG) of different HPMA:MAGG compositions (Figure 7). This has resulted in the 
deposition of HPMA-MAGG macromolecules on the surface of nanocomplexes and 
formation of PHPMA-based coating. Formation of this PHPMA-coating has resulted in the 
increase in the particle size from the original 148 nm to approximately 175 nm. The 
nanoparticles were tested for their permeation through porcine intestinal mucus mounted 
between semipermeable membranes using Ussing diffusion chamber. Additionally, the 
diffusivity of nanoparticles was also evaluated using multiple-particle tracking (MPT) 
method. The nanoparticles coated with less negatively charged HPMA-MAGG copolymers 
(containing lower quantities of MAGG) demonstrated better ability to diffuse through the 
mucus. The extra advantage of this system is the detachment of HPMA-MAGG 
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macromolecules in the mucus and release of insulin nanocomplexes with penetratin-
functionalised surface, which facilitates their subsequent penetration into cells.  These 
nanoparticles exhibited 20-fold greater absorption by mucus-secreting epithelium cells 
compared to free insulin and generated a substantial hypoglycemic response when orally 
administered in diabetic rats.   
 
Figure 7. Structures of PHPMA, HPMA:MAGG copolymers, PHEMA and PHEA  
More recently, Liu et al [77] reported a similar study, where insulin was incorporated into the 
core nanocomplex particles formed by trimethylchitosan and tripolyphosphate, which were 
subsequently coated with HPMA:MAGG (80:20 %) copolymer. The diffusion of the resulting 
nanoparticles through human cervicovaginal mucus was studied using MPT and Ussing 
chamber, similarly to [76]. The ensemble-averaged mean squared displacement (<MSD>) 
values determined using MPT technique for the diffusion in the mucus were found to be 9.6-
fold greater for the nanoparticles coated with HPMA:MAGG compared to uncoated particles. 
The apparent permeability coefficient of the nanoparticles coated with HPMA:MAGG was 
also 4.56-fold greater than for the core trimethylchitosan-tripolyphosphate nanoparticles, 
when estimated in a diffusion experiment using Ussing chamber. Both types of nanoparticles 
(coated and uncoated) were studied in vivo using diabetic rats. An oral administration of the 
nanoparticles with insulin demonstrated advantage in reducing blood glucose levels 
compared to free insulin solutions. The nanoparticles coated with HPMA:MAGG provided a 
larger relative bioavailability of 8.56% compared to 3.09% observed for uncoated particles at 
the dose of 50 IU/kg.  
In a subsequent study, Liu et al [78] explored the role of HPMA:MAGG molecular weight 
ranging within 17 to 120 kDa in the diffusion through mucus and epithelial cells. They used 
core-particles reported in [77] and coated them with HPMA:MAGG of different molecular 
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weights. The nanoparticles coated with 17 kDa HPMA:MAGG exhibited better permeability 
through mucus and highest stability. However, the best molecular weight of HPMA:MAGG 
to promote cell uptake was 26 kDa.  
Other hydrophilic polymers containing pendant hydroxyl groups are poly(2-
hydroxyethylmethacrylate (PHEMA) and poly(2-hydroxyethylacrylate) (PHEA) (Figure 7). 
PHEMA is a well-established hydrophilic polymer widely used for biomedical applications. 
The main areas of PHEMA applications include soft contact lenses, drug delivery devices and 
dental composites [79]. Although 2-hydroxyethylmethacrylate monomer is fully soluble in 
water, its linear polymer is insufficiently hydrophilic and swells in water to produce a gel. 
PHEA is more hydrophilic than PHEMA and it is fully soluble in water. To the best of our 
knowledge, there are currently no studies on the use of either PHEMA or PHEA to modify 
nanoparticle surfaces to facilitate their penetration through mucus. However, a recent study of 
the behaviour of HEMA:HEA copolymeric hydrogels in solutions of lysozyme indicated that 
the copolymers containing higher levels of HEA have a greater resistance to protein 
deposition [80]. This indicates that more hydrophilic PHEA will possibly be another mucus-
inert polymer that should facilitate penetration of PHEA-decorated nanoparticles through 
mucosal surfaces. Recent advances in controlled (co)polymerization of both 2-
hydroxyethylmethacrylate and 2-hydroxyethylacrylate using ATRP [81], nitroxide-mediated 
radical polymerization [82] and RAFT techniques [83] can provide these polymers with 
various well-defined architecture and low molecular weights required for the design of 
mucus-penetrating nanoparticles.  
Polyglycidols (PGs) are hydrophilic aliphatic polyether polyols that can potentially be 
synthesised with both branched and linear architecture (Figure 8) [84]. These materials were 
found to be highly biocompatible in a variety of both in vitro and in vivo assays [85]. In a 
study of protein adsorption, PG monolayers were found to be resistant similarly to PEG and 
are significantly better than dextran [86]. PGs were also considered as a potential alternative 
to PEG to protect surfaces of nanoparticles and ensure their “stealth” character [87]. 
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Figure 8. Structures of linear (a) and branched (b) polyglycidols. These structures reprinted 
from M. Gosecki, M. Gadzinowski, M. Gosecka, T. Basinska and S. Slomkowski, 
Polyglycidol, Its Derivatives, and Polyglycidol-Containing Copolymers—Synthesis and 
Medical Applications, Polymers 2016, 8(6), 227 under  ®2016 by MDPI 
(http://www.mdpi.org). 
 
Some polysaccharides such as low molecular weight dextran can also be expected to exhibit 
mucus-inert properties. Dextran is often used as a negative control in the studies of liquid and 
semisolid formulations due to its poor mucoadhesive properties [88, 89]. There are also 
reports on improved nanoparticles mobility in the mucus, mediated by guluronate oligomers 
prepared by acid hydrolysis of alginates [90].  
 
2.5. Zwitterionic polymers 
Zwitterionic polymers or polybetains are defined as materials, whose macromolecules have 
both anionic and cationic groups within their repeating unit [91-93]. Zwitterionic polymers 
have numerous technical applications including ion exchange raisins, chelators for water 
purification, sewage treatment, soil conditioning, reinforcement of paper, pigment retention, 
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and formulation in shampoos and hair conditioners [91]. Due to excellent biocompatibility, 
bioinert nature and hydrophilicity some polybetains have found applications as coatings for 
biomedical devices, drug delivery systems, and bioconjugates [92]. Figure 9 schematically 
shows various potential structures for polybetains. Depending on the nature of ionic groups, 
polybetaines may be classified into polycarboxybetaines, polysulfobetaines, and 
polyphosphobetaines. 
 
Figure 9. Distribution of ionic groups within polyzwitterionic polymers. Reprinted from A. 
Laschewsky, Structures and Synthesis of Zwitterionic Polymers, Polymers 2014, 6(5), 1544-
1601 [93] under  ®2014 by MDPI (http://www.mdpi.org).  
 
There are a number of studies demonstrating that polybetains have a “stealth” character and 
can greatly reduce non-specific protein adsorption, bacterial adhesion and biofilm formation 
[87]. For example, Yang et al [94] demonstrated that the nanoparticles coated with 
zwitterionic poly(carboxybetaine acrylamide) exhibit excellent stability in undiluted human 
blood serum and have superior performance compared to PEGylated particles.  
Shan et al [95] reported the design of self-assembled nanoparticles decorated with 
zwitterionic groups derived from dilauroylphosphatidylcholine (DLPC). They studied the 
effect of DLPC coating on the mucus permeation, cellular uptake and in vivo efficacy in oral 
delivery of insulin. The nanoparticles were prepared by mixing porcine insulin, poly(lactic 
acid) (PLA) and DLPC in dimethylsulfoxide. This mixture was then added to deionised water 
to cause precipitation and formation of nanoparticles. They studied these nanoparticles in 
comparison with PLA coated with Pluronic F127 (to result in PEGylated surfaces) and PVA. 
Mucus permeation studies were performed using four different approaches – mucin affinity 
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analysis, modified fluorescence recovery after photobleaching (FRAP) analysis, mucus 
diffusion analysis and small intestinal biodistribution study in vivo.  Both DLPC-coated and 
PEGylated particles exhibited minimal interaction with purified porcine mucin; however, 
PVA-coated particles caused 10-fold greater aggregation in 0.1 % mucin solution compared 
to DLPC-decorated particles. The FRAP analysis also demonstrated greater mobility of 
DLPC-coated and PEGylated particles compared to PVA-coated ones. The experiment on 
mucus diffusion estimated the apparent permeability coefficient of the nanoparticles and 
revealed 6.3-fold greater diffusivity of DLPC-coated system compared to the particles coated 
with PVA. In vivo biodistribution study performed in mice indicated that PVA-coated 
nanoparticles covered only 32.3±4.2 % of intestinal epithelium surface; whereas DLPC-
decorated and PEGylated particles gave 69.0±4.6 % and 73.0±5.0% surface coverage, 
respectively. Excellent diffusivity of the nanoparticles through mucus provided better 
intestinal distribution to ensure good therapeutic efficiency. The nanoparticles with 
zwitterionic surfaces also exhibited greater cellular uptake, which was more efficient than for 
PEGylated particles. In vivo oral administration of insulin-loaded zwitterionic nanoparticles 
in diabetic rats resulted in a greater bioavailability compared to PEGylated and PVA-
decorated nanoparticles as well as free insulin.  
 
3. Nanoparticles decorated with proteolytic enzymes 
Nanoparticles with enhanced mucus-penetrating properties could be designed not only using 
mucus-inert polymers but also active functional moieties, for example, mucolytic enzymes. 
Bernkop-Schnürch and co-workers [96] developed nanoparticles functionalised with papain, 
an enzyme with mucolytic activity. Papain was covalently linked to poly(acrylic acid) and 
calcium chloride solution was then added dropwise to the resulting enzyme-polymer 
conjugate to form nanoparticles as shown in Figure 10.   
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Figure 10. Scheme of synthesis of nanoparticles decorated with papain. Reprinted from 
European Journal of Pharmaceutics and Biopharmaceutics, Volume 87, Issue 1, Christiane 
Müller, Glen Perera, Verena König, Andreas Bernkop-Schnürch “Development and in vivo 
evaluation of papain-functionalized nanoparticles”, 125–131, ©2014 [96], with permission 
from Elsevier. 
The resulting nanoparticles were of 190-230 nm and had a negative zeta potential. For the 
mucus diffusion studies these nanoparticles were also loaded with fluorescein diacetate as a 
fluorescent marker. The rheological measurements indicated that the nanoparticles added to 
porcine intestinal mucus lead to a significant loss of its viscoelastic properties. The parent 
PAA without papain did not cause this dramatic reduction in mucus relative viscosity. The in 
vitro diffusion of the nanoparticles was studied using modified Transwell-Snapwell diffusion 
chambers and these experiments demonstrated that the nanoparticles formed by papain-
polymer conjugates have a 3.0-fold greater diffusivity compared to the particles formed by 
parent poly(acrylic acid). These nanoparticles together with several controls were 
encapsulated into enterically-coated microcapsules and studied in vivo experiments in rats 
using oral dosing. It was demonstrated that the nanoparticles with conjugated papain had a 
greater penetration through the mucus layer of proximal segments of the intestinal tract.  
In a subsequent study Bernkop-Schnürch and co-workers [97] have reported a comparison 
between the nanoparticles formed by poly(acrylic acid) conjugated with papain and 
bromelain. These studied the diffusivity of both types of nanoparticles and control samples in 
vitro using the rotating tube technique [98] and also pulsed-gradient spin-echo NMR 
spectroscopy [99].  The nanoparticles decorated with proteolytic enzymes exhibited greater 
mucus permeation compared to the particles formed by parent poly(acrylic acid) and 
bromelain-decorated particles were found to be more efficient than the particles with papain.  
 
 
4. Comparison of different systems 
Different polymer and biopolymer systems were considered in the previous sections as 
potential materials for surface modification of nanoparticles to facilitate their mucus 
penetration. This section will present a comparison of these materials and will discuss their 
advantages and disadvantages (Table 1).  
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Table 1. Comparison of different materials used for design of mucus-penetrating particles 
Materials used 
for 
functionalisation 
of nanoparticle 
surfaces 
References to 
the studies 
reporting 
their use to 
facilitate 
mucus-
penetration 
Advantages Disadvantages 
PEG [31, 34] The gold standard for 
stealth polymers in drug 
delivery [100]; FDA 
approved status [101]; 
excellent track record of 
applications in the design 
of mucus-penetrating 
particles 
Limited chemical stability, 
particularly due to 
oxidative degradation 
[102]; limited excretion 
from the body as for other 
polymers [101] 
POZ [47, 48]  A facile synthesis; 
possibility for further 
functionalisation [42]; a 
high degree of renal 
clearance 
with no bioaccumulation 
[103]; and improved 
stability against oxidative 
degradation [102]. 
Not approved by FDA yet 
PS * “Stealth” properties 
analogous to  
PEG (i.e., long circulation 
times and limited 
nonspecific organ uptake) 
[52] 
Only few studies reporting 
the biomedical 
applications of PS 
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PVA [68, 69] Generally Recognised as 
Safe (GRAS) by the FDA 
and approved for many 
pharmaceutical 
applications [69]; 
excellent surface-active 
properties and good track 
record of applications as a 
stabilizer and emulsifier 
Strong dependence of 
physicochemical and 
biological properties on 
the degree of deacetylation 
PHPMA [76-78] Widely explored as a 
carrier for anticancer 
agents with several 
products currently 
progressed through 
clinical trials [104] 
Non-biodegradable nature 
of this polymer and its 
derivatives may limit some 
clinical applications [105]; 
relatively expensive 
polymer compared to 
PEGs 
PHEMA  
and PHEA  
* Excellent biocompatibility 
of PHEMA with a proven 
non-irritation potential for 
mucosal tissues (e.g. 
application in contact lens 
industry) [61, 79].  
PHEMA is relatively 
hydrophobic and is not 
soluble in water. This may 
hamper diffusion of 
PHEMA decorated 
nanoparticles through 
mucus. Lack of biomedical 
studies involving PHEA 
PGs * Less susceptible to 
oxidation or thermal stress 
than PEG [86].  
Only a few studies 
reporting the use of PGs in 
drug delivery [106]. 
Zwitterionic 
polymers 
[95] These materials bind 
water molecules stronger 
than conventional water-
soluble polymers such as 
PEG;  they provide 
electrostatically induced 
Current lack of studies 
reporting the use of 
zwitterionic polymers in 
drug delivery 
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hydration that prevents 
adsorption of proteins, 
cells, and bacteria on 
surfaces;  poly(carboxy-
betaine) has better 
chemical stability 
compared to PEG [107] 
Proteolytic 
enzymes 
[96, 97] Provides mucolytic effects 
in addition to enhancing 
mucus penetration 
Potential issues with 
product long term stability 
as enzymatic activity may 
decrease with time 
*No particle permeation studies reported 
 
5. Conclusions 
PEGylated nanoparticles have been exploited as potential strategy to facilitate diffusion 
through mucosal barriers. Excellent biocompatibility, mucus inert nature and stealth character 
of PEGs ensure their application in the design of mucus-penetrating particles. Recent 
advances in the synthetic polymer and colloidal chemistry identified a number of water-
soluble polymers that could be used as alternatives to PEGs. Some classes of polymers such 
as poly(2-alkyl-2-oxazolines), poly(vinyl alcohols), other hydroxyl containing polymers and 
polybetains have been explored in their potential to facilitate diffusion through mucosal 
barriers. Some other materials such as polysarcosine, poly(2-hydroxyethyl(meth)acrylates) 
and polyglycydol could potentially be explored for this application.  There are still relatively 
few studies on the use of these polymers in the design of nanoparticles with enhanced mucus 
penetration. In some of these studies polymers were physically bound to particle surfaces to 
facilitate their diffusion (some of these macromolecules were even able to detach from the 
particles during their transit through the mucus); other reports describe chemical conjugation 
strategies in the design of mucus-penetrating systems. The general features of mucus-inert 
polymers suitable for the design of mucus-penetrating particles are their relatively low 
molecular weight, highly hydrophilic and non-charged nature. These polymers must be either 
fully non-ionic or should have a fully balanced number of positively and negatively-charged 
groups as in zwitterions. Methods of controlled polymerization developed in recent years 
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could help in the synthesis of well-defined mucus-inert polymers with low molecular weight 
and narrow polydispersity, which will facilitate the design of advanced mucus-penetrating 
drug delivery systems.  
In addition to mucus-inert polymers used for functionalisation of nanoparticles, other 
strategies could be used to enhance their penetration through mucosal barriers. One of the 
strategies is the application of mucolytic enzymes.  
It should also be noted that different research groups use a variety of techniques and mucus 
samples to study nanoparticle diffusion. The difference in these approaches may also affect 
the results greatly, and the direct comparison between the polymers that provide mucus-
penetrating properties is often difficult.  
 
6. References 
[1] V.V. Khutoryanskiy, Advances in Mucoadhesion and Mucoadhesive Polymers, Macromol Biosci, 
11 (2011) 748-764. 
[2] V.V. Khutoryanskiy, Mucoadhesive Materials and Drug Delivery Systems Preface, Mucoadhesive 
Materials and Drug Delivery Systems, (2014) Xvii-Xvii. 
[3] G.P. Andrews, T.P. Laverty, D.S. Jones, Mucoadhesive polymeric platforms for controlled drug 
delivery, Eur J Pharm Biopharm, 71 (2009) 505-518. 
[4] N.A. Peppas, J.B. Thomas, J. McGinty, Molecular Aspects of Mucoadhesive Carrier Development 
for Drug Delivery and Improved Absorption, J Biomat Sci-Polym E, 20 (2009) 1-20. 
[5] A.R. Mackie, F.M. Goycoolea, B. Menchicchi, C.M. Caramella, F. Saporito, S. Lee, K. Stephansen, 
I.S. Chronakis, M. Hiorth, M. Adamczak, M. Waldner, H.M. Nielsen, L. Marcelloni, Innovative 
Methods and Applications in Mucoadhesion Research, Macromol Biosci, (2017). 
[6] E. Mathiowitz, D.E. Chickering, C.-M. Lehr, Bioadhesive drug delivery systems : fundamentals, 
novel approaches, and development, Marcel Dekker, New York, 1999. 
[7] V. Lenaerts, R. Gurny, Bioadhesive drug delivery systems, CRC Press, Boca Raton, Fla., 1990. 
[8] S. Duggan, W. Cummins, O. O'Donovan, H. Hughes, E. Owens, Thiolated polymers as 
mucoadhesive drug delivery systems, Eur J Pharm Sci, 100 (2017) 64-78. 
[9] S. Lindert, J. Breitkreutz, Oromucosal multilayer films for tailor-made, controlled drug delivery, 
Expert opinion on drug delivery, (2017) 1-15. 
[10] A. Partenhauser, A. Bernkop-Schnurch, Mucoadhesive polymers in the treatment of dry X 
syndrome, Drug discovery today, 21 (2016) 1051-1062. 
[11] P. Schattling, E. Taipaleenmaki, Y. Zhang, B. Stadler, A Polymer Chemistry Point of View on 
Mucoadhesion and Mucopenetration, Macromol Biosci, (2017). 
[12] P.W. Morrison, V.V. Khutoryanskiy, Advances in ophthalmic drug delivery, Therapeutic delivery, 
5 (2014) 1297-1315. 
[13] B.M. Davis, E.M. Normando, L. Guo, L.A. Turner, S. Nizari, P. O'Shea, S.E. Moss, S. Somavarapu, 
M.F. Cordeiro, Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin 
A5-associated Liposomes, Small, 10 (2014) 1575-1584. 
[14] M. Kapoor, J.C. Cloyd, R.A. Siegel, A review of intranasal formulations for the treatment of 
seizure emergencies, J Control Release, 237 (2016) 147-159. 
22 
 
[15] L. Kozlovskaya, M. Abou-Kaoud, D. Stepensky, Quantitative analysis of drug delivery to the brain 
via nasal route, J Control Release, 189 (2014) 133-140. 
[16] M.T. Cook, S.A. Schmidt, E. Lee, W. Samprasit, P. Opanasopit, V.V. Khutoryanskiy, Synthesis of 
mucoadhesive thiol-bearing microgels from 2-(acetylthio)ethylacrylate and 2-
hydroxyethylmethacrylate: novel drug delivery systems for chemotherapeutic agents to the bladder, 
J Mater Chem B, 3 (2015) 6599-6604. 
[17] S. GuhaSarkar, R. Banerjee, Intravesical drug delivery: Challenges, current status, opportunities 
and novel strategies, J Control Release, 148 (2010) 147-159. 
[18] K.R. Bhaskar, P. Garik, B.S. Turner, J.D. Bradley, R. Bansil, H.E. Stanley, J.T. Lamont, Viscous 
Fingering of Hcl through Gastric Mucin, Nature, 360 (1992) 458-461. 
[19] M.T. Cook, G. Tzortzis, D. Charalampopoulos, V.V. Khutoryanskiy, Microencapsulation of 
probiotics for gastrointestinal delivery, J Control Release, 162 (2012) 56-67. 
[20] J. das Neves, M. Amiji, B. Sarmento, Mucoadhesive nanosystems for vaginal microbicide 
development: friend or foe?, Wires Nanomed Nanobi, 3 (2011) 389-399. 
[21] S.K. Lai, Y.Y. Wang, J. Hanes, Mucus-penetrating nanoparticles for drug and gene delivery to 
mucosal tissues, Adv Drug Deliver Rev, 61 (2009) 158-171. 
[22] H.H. Sigurdsson, J. Kirch, C.M. Lehr, Mucus as a barrier to lipophilic drugs, Int J Pharmaceut, 453 
(2013) 56-64. 
[23] M. Ruponen, A. Urtti, Undefined role of mucus as a barrier in ocular drug delivery, Eur J Pharm 
Biopharm, 96 (2015) 442-446. 
[24] A. Sosnik, J. das Neves, B. Sarmento, Mucoadhesive polymers in the design of nano-drug 
delivery systems for administration by non-parenteral routes: A review, Prog Polym Sci, 39 (2014) 
2030-2075. 
[25] C.S. Schneider, Q. Xu, N.J. Boylan, J. Chisholm, B.C. Tang, B.S. Schuster, A. Henning, L.M. Ensign, 
E. Lee, P. Adstamongkonkul, B.W. Simons, S.S. Wang, X. Gong, T. Yu, M.P. Boyle, J.S. Suk, J. Hanes, 
Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways 
following inhalation, Science advances, 3 (2017) e1601556. 
[26] N.N. Sanders, S.C. De Smedt, E. Van Rompaey, P. Simoens, F. De Baets, J. Demeester, Cystic 
fibrosis sputum - A barrier to the transport of nanospheres, Am J Resp Crit Care, 162 (2000) 1905-
1911. 
[27] P.G. Bhat, D.R. Flanagan, M.D. Donovan, Drug diffusion through cystic fibrotic mucus: Steady-
state permeation, rheologic properties, and glycoprotein morphology, J Pharm Sci, 85 (1996) 624-
630. 
[28] K.J. Whaley, J. Hanes, R. Shattock, R.A. Cone, D.R. Friend, Novel Approaches to Vaginal Delivery 
and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines, Antivir Res, 88 (2010) 
S55-S66. 
[29] D. Lopes, C. Nunes, M.C.L. Martins, B. Sarmento, S. Reis, Eradication of Helicobacter pylori: Past, 
present and future, J Control Release, 189 (2014) 169-186. 
[30] Y.Y. Wang, S.K. Lai, J.S. Suk, A. Pace, R. Cone, J. Hanes, Addressing the PEG Mucoadhesivity 
Paradox to Engineer Nanoparticles that "Slip" through the Human Mucus Barrier, Angew Chem Int 
Edit, 47 (2008) 9726-9729. 
[31] M. Yang, S.K. Lai, Y.Y. Wang, W.X. Zhong, C. Happe, M. Zhang, J. Fu, J. Hanes, Biodegradable 
Nanoparticles Composed Entirely of Safe Materials that Rapidly Penetrate Human Mucus, Angew 
Chem Int Edit, 50 (2011) 2597-2600. 
[32] O. Mert, S.K. Lai, L. Ensign, M. Yang, Y.Y. Wang, J. Wood, J. Hanes, A poly(ethylene glycol)-based 
surfactant for formulation of drug-loaded mucus penetrating particles, J Control Release, 157 (2012) 
455-460. 
[33] Q.G. Xu, N.J. Boylan, S.T. Cai, B. Miao, H. Patel, J. Hanes, Scalable method to produce 
biodegradable nanoparticles that rapidly penetrate human mucus, J Control Release, 170 (2013) 
279-286. 
23 
 
[34] S.K. Lai, D.E. O'Hanlon, S. Harrold, S.T. Man, Y.Y. Wang, R. Cone, J. Hanes, Rapid transport of 
large polymeric nanoparticles in fresh undiluted human mucus, P Natl Acad Sci USA, 104 (2007) 
1482-1487. 
[35] K. Maisel, M. Reddy, Q.G. Xu, S. Chattopadhyay, R. Cone, L.M. Ensign, J. Hanes, Nanoparticles 
coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal 
distribution in vivo, Nanomedicine-Uk, 11 (2016) 1337-1343. 
[36] J.S. Suk, S.K. Lai, N.J. Boylan, M.R. Dawson, M.P. Boyle, J. Hanes, Rapid transport of muco-inert 
nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine, Nanomedicine-Uk, 6 (2011) 
365-375. 
[37] L.M. Ensign, R. Cone, J. Hanes, Oral drug delivery with polymeric nanoparticles: The 
gastrointestinal mucus barriers, Adv Drug Deliver Rev, 64 (2012) 557-570. 
[38] I.P. de Sousa, T. Moser, C. Steiner, B. Fichtl, A. Bernkop-Schnurch, Insulin loaded mucus 
permeating nanoparticles: Addressing the surface characteristics as feature to improve mucus 
permeation, Int J Pharmaceut, 500 (2016) 236-244. 
[39] Q.G. Xu, N.J. Boylan, J.S. Suk, Y.Y. Wang, E.A. Nance, J.C. Yang, P.J. McDonnell, R.A. Cone, E.J. 
Duh, J. Hanes, Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo, J Control 
Release, 167 (2013) 76-84. 
[40] N.N. Sanders, L. Peeters, I. Lentacker, J. Demeester, S.C. De Smedt, Wanted and unwanted 
properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer, J Control Release, 
122 (2007) 226-235. 
[41] E.A. Mun, P.W.J. Morrison, A.C. Williams, V.V. Khutoryanskiy, On the Barrier Properties of the 
Cornea: A Microscopy Study of the Penetration of Fluorescent ly Labeled Nanoparticles, Polymers, 
and Sodium Fluorescein, Mol Pharmaceut, 11 (2014) 3556-3564. 
[42] R. Hoogenboom, Poly(2-oxazoline)s: A Polymer Class with Numerous Potential Applications, 
Angew Chem Int Edit, 48 (2009) 7978-7994. 
[43] O. Sedlacek, B.D. Monnery, S.K. Filippov, R. Hoogenboom, M. Hruby, Poly(2-Oxazoline)s - Are 
They More Advantageous for Biomedical Applications Than Other Polymers?, Macromol Rapid 
Comm, 33 (2012) 1648-1662. 
[44] T.X. Viegas, M.D. Bentley, J.M. Harris, Z.F. Fang, K. Yoon, B. Dizman, R. Weimer, A. Mero, G. 
Pasut, F.M. Veronese, Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery, 
Bioconjugate Chem, 22 (2011) 976-986. 
[45] M.N. Macgregor-Ramiasa, A.A. Cavallaro, K. Vasilev, Properties and reactivity of polyoxazoline 
plasma polymer films, J Mater Chem B, 3 (2015) 6327-6337. 
[46] Clinical trial number: NCT02579473, in. 
[47] E.D.H. Mansfield, V.R. de la Rosa, R.M. Kowalczyk, I. Grillo, R. Hoogenboom, K. Sillence, P. Hole, 
A.C. Williams, V.V. Khutoryanskiy, Side chain variations radically alter the diffusion ofpoly(2-alkyl-2-
oxazoline) functionalised nanoparticles through a mucosal barrier, Biomater Sci-Uk, 4 (2016) 1318-
1327. 
[48] E.D.H. Mansfield, K. Sillence, P. Hole, A.C. Williams, V.V. Khutoryanskiy, POZylation: a new 
approach to enhance nanoparticle diffusion through mucosal barriers, Nanoscale, 7 (2015) 13671-
13679. 
[49] G.S. Irmukhametova, G.A. Mun, V.V. Khutoryanskiy, Thiolated Mucoadhesive and PEGylated 
Nonmucoadhesive Organosilica Nanoparticles from 3-Mercaptopropyltrimethoxysilane, Langmuir, 
27 (2011) 9551-9556. 
[50] E.A. Mun, A.C. Williams, V.V. Khutoryanskiy, Adhesion of thiolated silica nanoparticles to urinary 
bladder mucosa: Effects of PEGylation, thiol content and particle size, Int J Pharmaceut, 512 (2016) 
32-38. 
[51] T.J. Deming, Synthetic polypeptides for biomedical applications, Prog Polym Sci, 32 (2007) 858-
875. 
[52] D.H. Zhang, S.H. Lahasky, L. Guo, C.U. Lee, M. Lavan, Polypeptoid Materials: Current Status and 
Future Perspectives, Macromolecules, 45 (2012) 5833-5841. 
24 
 
[53] A. Fokina, K. Klinker, L. Braun, B.G. Jeong, W.K. Bae, M. Barz, R. Zentel, Multidentate 
Polysarcosine-Based Ligands for Water-Soluble Quantum Dots, Macromolecules, 49 (2016) 3663-
3671. 
[54] H. Zhu, Y. Chen, F.J. Yan, J. Chen, X.F. Tao, J. Ling, B. Yang, Q.J. He, Z.W. Mao, Polysarcosine 
brush stabilized gold nanorods for in vivo near-infrared photothermal tumor therapy, Acta Biomater, 
50 (2017) 534-545. 
[55] K.H.A. Lau, C.L. Ren, T.S. Sileika, S.H. Park, I. Szleifer, P.B. Messersmith, Surface-Grafted 
Polysarcosine as a Peptoid Antifouling Polymer Brush, Langmuir, 28 (2012) 16099-16107. 
[56] N. Ben Halima, Poly(vinyl alcohol): review of its promising applications and insights into 
biodegradation, Rsc Adv, 6 (2016) 39823-39832. 
[57] E.A. Kamoun, X. Chen, M.S.M. Eldin, E.R.S. Kenawy, Crosslinked poly(vinyl alcohol) hydrogels for 
wound dressing applications: A review of remarkably blended polymers, Arab J Chem, 8 (2015) 1-14. 
[58] G. Verstraete, W. De Jaeghere, J. Vercruysse, W. Grymonpre, V. Vanhoorne, F. Stauffer, T. De 
Beer, A. Bezuijen, J.P. Remon, C. Vervaet, The use of partially hydrolysed polyvinyl alcohol for the 
production of high drug-loaded sustained release pellets via extrusion-spheronisation and coating: In 
vitro and in vivo evaluation, Int J Pharmaceut, 517 (2017) 88-95. 
[59] W. De Jaeghere, T. De Beer, J. Van Bocxlaer, J.P. Remon, C. Vervaet, Hot-melt extrusion of 
polyvinyl alcohol for oral immediate release applications, Int J Pharm, 492 (2015) 1-9. 
[60] E. Calo, J.M.S. de Barros, M. Fernandez-Gutierrez, J. San Roman, L. Ballamy, V.V. Khutoryanskiy, 
Antimicrobial hydrogels based on autoclaved poly(vinyl alcohol) and poly(methyl vinyl ether-alt-
maleic anhydride) mixtures for wound care applications, Rsc Adv, 6 (2016) 55211-55219. 
[61] E. Calo, V.V. Khutoryanskiy, Biomedical applications of hydrogels: A review of patents and 
commercial products, Eur Polym J, 65 (2015) 252-267. 
[62] L. Mu, S.S. Feng, Fabrication, characterization and in vitro release of paclitaxel (Taxol (R)) loaded 
poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol 
emulsifiers, J Control Release, 76 (2001) 239-254. 
[63] R. Saadati, S. Dadashzadeh, Marked effects of combined TPGS and PVA emulsifiers in the 
fabrication of etoposide-loaded PLGA-PEG nanoparticles: In vitro and in vivo evaluation, Int J 
Pharmaceut, 464 (2014) 135-144. 
[64] P. Molyneux, Water-soluble synthetic polymers : properties and behavior, CRC Press, Boca 
Raton, Fla., 1984. 
[65] G.G. de Lima, R.O. de Souza, A.D. Bozzi, M.A. Poplawska, D.M. Devine, M.J.D. Nugent, Extraction 
Method Plays Critical Role in Antibacterial Activity of Propolis-Loaded Hydrogels, J Pharm Sci, 105 
(2016) 1248-1257. 
[66] H.J. Jiang, G. Campbell, D. Boughner, W.K. Wan, M. Quantz, Design and manufacture of a 
polyvinyl alcohol (PVA) cryogel tri-leaflet heart valve prosthesis, Med Eng Phys, 26 (2004) 269-277. 
[67] E. Calo, J. Barros, L. Ballamy, V.V. Khutoryanskiy, Poly(vinyl alcohol)-Gantrez (R) AN cryogels for 
wound care applications, Rsc Adv, 6 (2016) 105487-105494. 
[68] M. Yang, S.K. Lai, T. Yu, Y.Y. Wang, C. Happe, W.X. Zhong, M. Zhang, A. Anonuevo, C. Fridley, A. 
Hung, J. Fu, J. Hanes, Nanoparticle penetration of human cervicovaginal mucus: The effect of 
polyvinyl alcohol, J Control Release, 192 (2014) 202-208. 
[69] A. Popov, E. Enlow, J. Bourassa, H.M. Chen, Mucus-penetrating nanoparticles made with 
"mucoadhesive" poly(vinyl alcohol), Nanomed-Nanotechnol, 12 (2016) 1863-1871. 
[70] T. Congdon, P. Shaw, M.I. Gibson, Thermoresponsive, well-defined, poly(vinyl alcohol) co-
polymers, Polym Chem-Uk, 6 (2015) 4749-4757. 
[71] O.A. Scherman, H.M. Kim, R.H. Grubbs, Synthesis of well-defined poly((vinyl alcohol)(2)-alt-
methylene) via ring-opening metathesis polymerization, Macromolecules, 35 (2002) 5366-5371. 
[72] J. Kopecek, P. Kopeckova, HPMA copolymers: Origins, early developments, present, and future, 
Adv Drug Deliver Rev, 62 (2010) 122-149. 
[73] B.S. Tucker, B.S. Sumerlin, Poly(N-(2-hydroxypropyl) methacrylamide)-based nanotherapeutics, 
Polym Chem-Uk, 5 (2014) 1566-1572. 
25 
 
[74] M. Talelli, C.J.F. Rijcken, C.F. van Nostrum, G. Storm, W.E. Hennink, Micelles based on HPMA 
copolymers, Adv Drug Deliver Rev, 62 (2010) 231-239. 
[75] N. Du, W.X. Guo, Q.S. Yu, S.L. Guan, L.Y. Guo, T. Shen, H. Tang, Z.H. Gan, Poly(D,L-lactic acid)-
block-poly(N-(2-hydroxypropyl) methacrylamide) nanoparticles for overcoming accelerated blood 
clearance and achieving efficient anti-tumor therapy, Polym Chem-Uk, 7 (2016) 5719-5729. 
[76] W. Shan, X. Zhu, M. Liu, L. Li, J.J. Zhong, W. Sun, Z.R. Zhang, Y. Huang, Overcoming the Diffusion 
Barrier of Mucus and Absorption Barrier of Epithelium by Self-Assembled Nanoparticles for Oral 
Delivery of Insulin, Acs Nano, 9 (2015) 2345-2356. 
[77] M. Liu, J. Zhang, X. Zhu, W. Shan, L. Li, J.J. Zhong, Z.R. Zhang, Y. Huang, Efficient mucus 
permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan 
nanoparticles for oral insulin delivery, J Control Release, 222 (2016) 67-77. 
[78] M. Liu, L. Wu, X. Zhu, W. Shan, L. Li, Y. Cui, Y. Huang, Core-shell stability of nanoparticles plays 
an important role for overcoming the intestinal mucus and epithelium barrier, J Mater Chem B, 4 
(2016) 5831-5841. 
[79] J.P. Montheard, M. Chatzopoulos, D. Chappard, 2-Hydroxyethyl Methacrylate (Hema) - 
Chemical-Properties and Applications in Biomedical Fields, J Macromol Sci R M C, C32 (1992) 1-34. 
[80] E.V. Hackl, V.V. Khutoryanskiy, I. Ermolina, Hydrogels based on copolymers of 2-
hydroxyethylmethacrylate and 2-hydroxyethylacrylate as a delivery system for proteins: Interactions 
with lysozyme, J Appl Polym Sci, 134 (2017). 
[81] A. Muhlebach, S.G. Gaynor, K. Matyjaszewski, Synthesis of amphiphilic block copolymers by 
atom transfer radical polymerization (ATRP), Macromolecules, 31 (1998) 6046-6052. 
[82] K. Bian, M.F. Cunningham, Nitroxide-mediated living radical polymerization of 2-hydroxyethyl 
acrylate and the synthesis of amphiphilic block copolymers, Macromolecules, 38 (2005) 695-701. 
[83] H. Kakwere, S. Perrier, Facile Synthesis of Star-Shaped Copolymers via Combination of RAFT and 
Ring Opening Polymerization, J Polym Sci Pol Chem, 47 (2009) 6396-6408. 
[84] M. Gosecki, M. Gadzinowski, M. Gosecka, T. Basinska, S. Slomkowski, Polyglycidol, Its 
Derivatives, and Polyglycidol-Containing Copolymers - Synthesis and Medical Applications, Polymers-
Basel, 8 (2016). 
[85] R.K. Kainthan, J. Janzen, E. Levin, D.V. Devine, D.E. Brooks, Biocompatibility testing of branched 
and linear polyglycidol, Biomacromolecules, 7 (2006) 703-709. 
[86] C. Siegers, M. Biesalski, R. Haag, Self-assembled monolayers of dendritic polyglycerol derivatives 
on gold that resist the adsorption of proteins, Chem-Eur J, 10 (2004) 2831-2838. 
[87] Z. Amoozgar, Y. Yeo, Recent advances in stealth coating of nanoparticle drug delivery systems, 
Wires Nanomed Nanobi, 4 (2012) 219-233. 
[88] M.T. Cook, S.L. Smith, V.V. Khutoryanskiy, Novel glycopolymer hydrogels as mucosa-mimetic 
materials to reduce animal testing, Chem Commun, 51 (2015) 14447-14450. 
[89] P. Tonglairoum, R.P. Brannigan, P. Opanasopit, V.V. Khutoryanskiy, Maleimide-bearing nanogels 
as novel mucoadhesive materials for drug delivery, J Mater Chem B, 4 (2016) 6581-6587. 
[90] C.T. Nordgard, U. Nonstad, M.O. Olderoy, T. Espevik, K.I. Draget, Alterations in Mucus Barrier 
Function and Matrix Structure Induced by Guluronate Oligomers, Biomacromolecules, 15 (2014) 
2294-2300. 
[91] A.B. Lowe, C.L. McCormick, Synthesis and solution properties of zwitterionic polymers, Chem 
Rev, 102 (2002) 4177-4189. 
[92] S. Kudaibergenov, W. Jaeger, A. Laschewsky, Polymeric betaines: Synthesis, characterization, 
and application, Adv Polym Sci, 201 (2006) 157-224. 
[93] A. Laschewsky, Structures and Synthesis of Zwitterionic Polymers, Polymers-Basel, 6 (2014) 
1544-1601. 
[94] W. Yang, L. Zhang, S.L. Wang, A.D. White, S.Y. Jiang, Functionalizable and ultra stable 
nanoparticles coated with zwitterionic poly(carboxybetaine) in undiluted blood serum, Biomaterials, 
30 (2009) 5617-5621. 
26 
 
[95] W. Shan, X. Zhu, W. Tao, Y. Cui, M. Liu, L. Wu, L. Li, Y.X. Zheng, Y. Huang, Enhanced Oral Delivery 
of Protein Drugs Using Zwitterion-Functionalized Nanoparticles to Overcome both the Diffusion and 
Absorption Barriers, Acs Appl Mater Inter, 8 (2016) 25444-25453. 
[96] C. Muller, G. Perera, V. Konig, A. Bernkop-Schnurch, Development and in vivo evaluation of 
papain-functionalized nanoparticles, Eur J Pharm Biopharm, 87 (2014) 125-131. 
[97] I.P. de Sousa, B. Cattoz, M.D. Wilcox, P.C. Griffiths, R. Dalgliesh, S. Rogers, A. Bernkop-Schnurch, 
Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus 
barrier, Eur J Pharm Biopharm, 97 (2015) 257-264. 
[98] I.P. de Sousa, C. Steiner, M. Schmutzler, M.D. Wilcox, G.J. Veldhuis, J.P. Pearson, C.W. Huck, W. 
Salvenmoser, A. Bernkop-Schnurch, Mucus permeating carriers: formulation and characterization of 
highly densely charged nanoparticles, Eur J Pharm Biopharm, 97 (2015) 273-279. 
[99] P. Occhipinti, P.C. Griffiths, Quantifying diffusion in mucosal systems by pulsed-gradient spin-
echo NMR, Adv Drug Deliver Rev, 60 (2008) 1570-1582. 
[100] S. Grund, M. Bauer, D. Fischer, Polymers in Drug Delivery-State of the Art and Future Trends, 
Adv Eng Mater, 13 (2011) B61-B87. 
[101] F.M. Veronese, G. Pasut, PEGylation, successful approach to drug delivery, Drug discovery 
today, 10 (2005) 1451-1458. 
[102] Y. Chen, B. Pidhatika, T. von Erlach, R. Konradi, M. Textor, H. Hall, T. Luhmann, Comparative 
assessment of the stability of nonfouling poly(2-methyl-2-oxazoline) and poly(ethylene glycol) 
surface films: An in vitro cell culture study, Biointerphases, 9 (2014). 
[103] F.C. Gaertner, R. Luxenhofer, B. Blechert, R. Jordan, M. Essler, Synthesis, biodistribution and 
excretion of radiolabeled poly(2-alkyl-2-oxazoline)s, J Control Release, 119 (2007) 291-300. 
[104] R. Duncan, Development of HPMA copolymer-anticancer conjugates: Clinical experience and 
lessons learnt, Adv Drug Deliver Rev, 61 (2009) 1131-1148. 
[105] P. Goddard, I. Williamson, J. Brown, L.E. Hutchinson, J. Nicholls, K. Petrak, Soluble Polymeric 
Carriers for Drug Delivery .4. Tissue Autoradiography, and Whole-Body Tissue Distribution in Mice, of 
N-(2-Hydroxypropyl)Methacrylamide Copolymers Following Intravenous Administration, J Bioact 
Compat Pol, 6 (1991) 4-24. 
[106] K. Maruyama, S. Okuizumi, O. Ishida, H. Yamauchi, H. Kikuchi, M. Iwatsuru, Phosphatidyl 
Polyglycerols Prolong Liposome Circulation in-Vivo, Int J Pharmaceut, 111 (1994) 103-107. 
[107] S. Salmaso, P. Caliceti, Stealth properties to improve therapeutic efficacy of drug nanocarriers, 
Journal of drug delivery, 2013 (2013) 374252. 
 
 
